- CA$19.91m
- CA$20.18m
- CA$16.48m
- 90
- 63
- 50
- 77
Annual cashflow statement for NexgenRx, fiscal year end - December 31st, CAD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | 2.12 | 4.02 | -0.022 | -0.332 | 0.615 |
| Depreciation | |||||
| Amortisation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 0.187 | 0.069 | 0.089 | 0.062 | 0.045 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -0.287 | 0.425 | -0.582 | 0.229 | -1.14 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Taxes Payable | |||||
| Change in Other Liabilities | |||||
| Net Change in Other Assets & Liabilities | |||||
| Cash from Operating Activities | 2.65 | 3.82 | 1.07 | 1.28 | 1.15 |
| Capital Expenditures | -0.121 | -0.127 | -0.389 | -0.077 | -0.318 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | -0.957 | -1.24 | -0.118 | -0.171 | -0.181 |
| Purchase of Investments | |||||
| Cash from Investing Activities | -1.08 | -1.37 | -0.507 | -0.248 | -0.498 |
| Total Cash Dividends Paid | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | -1.3 | -0.94 | -1.11 | -0.919 | -0.823 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 0.275 | 1.52 | -0.55 | 0.11 | -0.171 |